SecurityHALO / Halozyme Therapeutics, Inc. (40637H109)
Latest Market Date2018-10-17
Short Volume35,644
Market Volume 854,000
Short Percent 4%

Short Interest and Volume

HALO / Halozyme Therapeutics, Inc. short volume is shown in the following chart. Short Volume is a data set that can be used to understand investor sentiment. When an investor makes a short sale, they do so with the belief that a security will decline in price. If the short sale volume increases as a percentage of the total volume, then that suggests a bearish (negative) sentiment by the market. If short sale volume decreases as a percentage of total volume, then that suggests a bullish (positive) sentiment.

Short Volume
Total number of short shares traded on the major US markets each day
Short Percent
Total number of short shares traded divided by the total shares traded each day
Short Interest
Total number of open short positions of a security, divided by the total float (not shown)
Short Squeeze
When a company with a high degree of short interest increases in price, which forces short sellers to "cover" their short interest buy buying actual shares, which in turn drives the price up even further.

Note that Short Percent on this page is not the same as Short Interest. Short Interest is a measure of the number of open short positions of a security, divided by the total float. Short Percent is the daily short volume divided by the total volume. Short Interest is not available for this security at this time.

Market Date Total Volume Short Volume Short Percent
2018-10-17 854,000 35,644 4.17
2018-10-16 1,688,600 92,047 5.45
2018-10-15 1,536,200 86,868 5.65
2018-10-12 1,547,200 101,309 6.55
2018-10-11 2,911,800 296,490 10.18
2018-10-10 1,919,000 57,018 2.97
2018-10-09 1,489,000 55,933 3.76
2018-10-08 1,526,600 46,658 3.06
2018-10-05 1,717,400 38,593 2.25
2018-10-04 1,451,600 32,016 2.21
HALO: Halozyme Therapeutics Analysis and Research Report

2018-02-13 - Asif

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel oncology therapies. The company's proprietary enzymes are used to facilitate the delivery of injected drugs and fluids, potentially enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for potential clinical benefit. The company exploit its technology and expertise using a two pillar strategy that the company believe enables it to manage risk and cost by: (1) developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and (2) licensing its technology to biopharmaceutical companies to collaboratively develop products that combine its technology with the collaborators’ proprietary compounds. The majority of its approved product and product candidates are based on rHuPH20, its patented recombinant human hyaluronidase enzyme. The company's proprietary development pipeline con...

Related News Stories

Stocks To Watch: Spotlight On Banks, Google Hardware And IPOs

2018-10-06 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (320-4)

Top Analyst Upgrades and Downgrades: Aetna, Analog Devices, Lowe’s, Merck, Pfizer, Plug Power, Qualcomm, Target and More

2018-08-23 247wallst
Stocks were indicated to open lower on Thursday morning, though the S&P 500 hit an all-time high earlier in the week. Earnings season is all but over now and was quite strong, with more than 70% of the companies exceeding expectations. Despite the gains in the market, 2018 has been choppy, and investors have seen less reward in buying every dip than they had been used to in recent years. Many investors also are trying to decide how they want their investments positioned ahead of the midterm elections and given international trade concerns. (44-1)

A Glimpse into the Pancreatic Cancer Pipeline

2018-08-23 biospace
The passing of singing great Aretha Franklin has focused attention on pancreatic cancer. Franklin, 76, succumbed to a neuroendocrine tumor of the pancreas. According to the National Cancer Institute (NCI), pancreatic cancer is relatively rare, with about 55,440 cases diagnosed annually, representing about 3.2 percent of new cancer cases. But each year, 44,330 Americans die from the disease, or about 7. (0-1)

Halozyme: A Look At The Q2 2018 Earnings

2018-08-19 seekingalpha
Halozyme Therapeutics (NASDAQ:HALO) is a robust grower that is operating near its growth inflection. Most investment risks are now significantly deleveraged due to the increasing sales from the approved molecules. Despite that that the partnered products in commercialization are delivering meaningful sales, there are substantial unlocked values in the developing pipeline. In the past 52-week, the stock traded up by $4.

Halozyme Therapeutics (HALO) Reports Q2 Loss, Tops Revenue Estimates

2018-08-08 zacks
Halozyme Therapeutics (HALO - Free Report) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items. (2-0)

CUSIP: 40637H109